PMC:7299399 / 27530-27712 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T115","span":{"begin":37,"end":49},"obj":"Body_part"}],"attributes":[{"id":"A115","pred":"fma_id","subj":"T115","obj":"http://purl.org/sig/ont/fma/fma62925"}],"text":"A full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with the saponin-based Matrix M developed by Novavax is in Phase I clinical testing (NCT04368988).89"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T103","span":{"begin":26,"end":34},"obj":"Disease"}],"attributes":[{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"A full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with the saponin-based Matrix M developed by Novavax is in Phase I clinical testing (NCT04368988).89"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T268","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T269","span":{"begin":158,"end":165},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"A full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with the saponin-based Matrix M developed by Novavax is in Phase I clinical testing (NCT04368988).89"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T204","span":{"begin":37,"end":49},"obj":"Chemical"},{"id":"T205","span":{"begin":50,"end":62},"obj":"Chemical"},{"id":"T206","span":{"begin":91,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A204","pred":"chebi_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A205","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A206","pred":"chebi_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/CHEBI_26605"}],"text":"A full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with the saponin-based Matrix M developed by Novavax is in Phase I clinical testing (NCT04368988).89"}

{"project":"LitCovid-sentences","denotations":[{"id":"T107","span":{"begin":0,"end":182},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with the saponin-based Matrix M developed by Novavax is in Phase I clinical testing (NCT04368988).89"}

{"project":"LitCovid-PubTator","denotations":[{"id":"415","span":{"begin":26,"end":36},"obj":"Species"},{"id":"416","span":{"begin":91,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A415","pred":"tao:has_database_id","subj":"415","obj":"Tax:2697049"},{"id":"A416","pred":"tao:has_database_id","subj":"416","obj":"MESH:D012503"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with the saponin-based Matrix M developed by Novavax is in Phase I clinical testing (NCT04368988).89"}